Medpace Holdings, Inc. (MEDP) Stock
MEDP has an Alpha Score of 58 out of 100 (moderate), computed on Oct 31, 2026 from 3 of 4 sub-scores. 6 members of Congress disclosed 21 trades in MEDP since 2020: 9 purchases and 12 sales, most recently David J. Taylor (purchase, May 15, 2026). 6 of the hedge funds AlphaScala tracks reported MEDP in 13F filings for the quarter ended Sep 30, 2026; the largest reported position is Renaissance Technologies's at $220.09M. Company insiders reported 0 open-market buys and 31 sales on SEC Form 4 in the 90 days to Nov 2, 2026. Its trailing P/E ratio is 37.3 and its net margin 17.7% (key statistics as of Oct 22, 2026).
What is MEDP's Alpha Score?
How it works →Alpha Score of 58 reflects moderate overall profile with strong momentum, poor value, strong quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.
Computed from 3 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Oct 31, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which members of Congress traded Medpace Holdings, Inc. (MEDP)?
Most recent: David J. Taylor (purchase, May 15, 2026); records start Oct 29, 2020.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Dave Taylor R-OH · House | 2026-05-15 | purchase | $1k – $15k |
| Dave Taylor R-OH · House | 2026-02-26 | purchase | $1k – $15k |
| Dave Taylor R-OH · House | 2026-01-29 | purchase | $1k – $15k |
| Dave Taylor R-OH · House | 2026-01-16 | sale | $1k – $15k |
| Gil Cisneros D-CA · House | 2026-01-15 | sale | $15k – $50k |
| Gil Cisneros D-CA · House | 2025-10-09 | partial sale | $1k – $15k |
| Lisa McClain R-MI · House | 2025-08-04 | sale | $1k – $15k |
| Gil Cisneros D-CA · House | 2025-07-24 | partial sale | $1k – $15k |
From STOCK Act periodic transaction reports. House filings as of Nov 1, 2026.
Every member of Congress who traded MEDP, with filing lags →Which hedge funds own MEDP?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Renaissance Technologies Jim Simons (founder) | 416K | $220.09M | -18% |
| D.E. Shaw David Shaw | 235K | $124.21M | -46% |
| Fundsmith Terry Smith | 52K | $27.74M | -16% |
| Marshall Wace | 29K | $15.45M | +196% |
| Bridgewater Associates Ray Dalio | 16K | $8.26M | -62% |
| Hussman Investment Trust John Hussman | 4K | $2.62M | -33% |
13F holdings as of Sep 30, 2026
Explore all tracked funds →Are Medpace Holdings, Inc. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Oct 29, 26 | Ewald Stephen P | General Counsel & Corp. Secy. | SELL | 1.2K | $859K |
| Oct 27, 26 | Burwig Susan E | Exec. VP, Operations | SELL | 3.9K | $2.7M |
| Oct 26, 26 | Burwig Susan E | Exec. VP, Operations | SELL | 16.1K | $10.9M |
| Sep 30, 26 | Troendle August J. | President & CEO | SELL | 22.0K | $13.7M |
| Sep 29, 26 | Troendle August J. | President & CEO | SELL | 26.7K | $16.6M |
| Sep 28, 26 | Troendle August J. | President & CEO | SELL | 2.4K | $1.5M |
| Sep 25, 26 | Troendle August J. | President & CEO | SELL | 154 | $96K |
| Sep 24, 26 | Troendle August J. | President & CEO | SELL | 27.8K | $17.3M |
| Sep 23, 26 | Troendle August J. | President & CEO | SELL | 16.1K | $10.1M |
| Sep 22, 26 | Troendle August J. | President & CEO | SELL | 49.0K | $30.8M |
SEC Form 4 filings as of Nov 2, 2026
See cluster-buy signals across all tickers →What are MEDP's key statistics?
Key statistics as of Oct 22, 2026
How does MEDP's valuation compare with the Healthcare sector?
| Metric | MEDP | Healthcare median | Companies in median |
|---|---|---|---|
| P/E ratio | 37.3 | 27.2 | 99 |
| Net margin | 17.67% | 4.85% | 143 |
| Return on equity | 110.15% | 6.68% | 162 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 3, 2026). P/E excludes loss-making companies.
MEDP price chart
Powered by TradingViewWhat does Medpace Holdings, Inc. do?
Medpace Holdings is a global, full-service clinical contract research organization that provides outsourced drug development and clinical trial services to biotechnology, pharmaceutical, and medical device companies. The firm specializes in comprehensive clinical development support across phases I through IV, offering services including clinical trial management, regulatory affairs, patient recruitment and retention, data management, medical writing, pharmacovigilance, bioanalytical laboratory services, and imaging capabilities. Medpace serves small and midsize biopharmaceutical sponsors that lack internal capacity to conduct trials independently, as well as larger pharmaceutical firms seeking specialized expertise. Operating across North America, Europe, Asia, South America, Africa, and Australia, Medpace combines scientific expertise with operational excellence to accelerate drug development timelines. Founded in 1992 and headquartered in Cincinnati, Ohio, the company supports the global outsourcing environment for clinical research and development, helping sponsors navigate complex regulatory requirements and bring new therapeutics to market efficiently.